Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 94Leukemia, Lymphocytic, Chronic, B-Cell 56Neoplasms 37Recurrence 28Lymphoma, Non-Hodgkin 25Myelodysplastic Syndromes 21Multiple Myeloma 18Leukemia 16Lymphoma, Large B-Cell, Diffuse 11Leukemia, Myelomonocytic, Chronic 10Hematologic Neoplasms 10Lymphoma, Mantle-Cell 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Lymphoma, B-Cell, Marginal Zone 6Leukemia, Myeloid 6Lymphoma 5Chromosome 17 deletion 5Lymphoma, B-Cell 4Breast Neoplasms 4Waldenstrom Macroglobulinemia 3Small Cell Lung Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Neuroblastoma 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Lymphoproliferative Disorders 2Hematologic Diseases 2GATA2 Deficiency 2

Interventions

Rituximab 8dacetuzumab 5blinatumomab 5ibrutinib 3Cyclophosphamide 3tetulomab tetraxetan lu-177 2ponatinib 2cobomarsen 2acalabrutinib 2Vincristine 2Prednisone 2Lutetium 2Ifosfamide 2Everolimus 2Etoposide 2Doxorubicin 2Carboplatin 2venetoclax 1sepantronium 1pomalidomide 1obinutuzumab 1fludarabine 1ficlatuzumab 1enzalutamide 1durvalumab 1denileukin diftitox 1cirmtuzumab 1amonafide 1Vorinostat 1Tinzaparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphatic Diseases × venetoclax × Clear all
NCT02265731 2021-08-02

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

AbbVie

Phase 1/2 Completed
38 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphatic Diseases, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡